dyslipidaemia


Also found in: Dictionary.

dyslipidaemia

Any disorder of lipid metabolism reflected in abnormal levels in the blood of cholesterol or triglycerides (fats).
References in periodicals archive ?
Lifestyle modification does not have impressive effects in children with dyslipidaemia.
013) in T2DM patients with CVD than in those without CVD, despite the fact that their use of medications for dyslipidaemia was much more common than in patients without CVD.
Prevention of HIV-related lipodystrophy is the best strategy and all HIV-infected persons should be screened at regular intervals for a history of metabolic disease, dyslipidaemia, DM, hypertension and alteration of body composition (Table 2).
NDH is often associated with a cluster of inter-related cardiovascular risk factors--hypertension, dyslipidaemia (with raised triglycerides and low HDL) and central obesity--and carries a high risk of progressing to T2DM.
Dyslipidaemia (disordered cholesterol)--along with smoking and hypertension--is a key modifiable risk factor for cardiovascular disease.
Release date- 23052013 - Bagsvaerd, Denmark, Novo Nordisk today announced the headline results from a 56-week double-blind phase 3a clinical trial investigating the potential ofliraglutide to induce and maintain weight loss in people without diabetes who are obese or overweight with comorbidities such as prediabetes, hypertension and dyslipidaemia.
High prevalence of diabetes, obesity and dyslipidaemia in urban slum population in northern India.
We plan to apply our team s first-hand experience in bringing a novel therapy for a rare dyslipidaemia to patients who have previously had no therapeutic alternatives.
In the Omani population, hypertension, diabetes, dyslipidaemia, sedentary occupations and smoking are major risk factors leading to mortality and morbidity due to heart and vascular malfunctioning.
The patient was a previously healthy active 74-year-old male with a past medical history including dyslipidaemia, Meniere's disease and a sigmoid colectomy 30 years previously.
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
The EU authorised sale for use in treating obese patients with a body mass index of 30 or more, type 2 diabetes patients with a body mass index of at least 27, or those with the prediabetic condition dyslipidaemia.